正在加载公司
Keep exploring
The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$1.36TA+
JNJJohnson & JohnsonUS$688.6BA+
MRKMerck & Co., Inc.US$364.3BA
NVSNovartis AGUS$306.3BA
AMGNAmgen Inc.US$251.9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
怎么赚钱
- Sales of prescription medicines
- Revenue from medicine partnerships
竞争对手
卖什么6
Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.
再显示 3 项
Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.
谁在买3
- Patients receive the medicines, usually after a clinician prescribes them.
- Hospitals, clinics and pharmacies purchase or dispense medicines for patients.
- Government health systems and private insurers may pay for or reimburse medicines.
靠什么支撑，什么会击垮它
业务依赖什么
- 1Sales of many medicines depend on patents and other protections that limit competing generic or biosimilar versions.
- 2Some medicines are developed or commercialised with partners, so their sales and revenue depend partly on those arrangements.
- 3Sales in China are affected by government volume-based purchasing and reimbursement decisions.
可能出什么问题
- 1Generic competition can reduce sales when patents expire or competitors enter early; the company reported generic entry affecting Farxiga and Brilinta.
- 2Clinical trials can fail to show that a medicine works, as occurred in the Wainua heart-disease trial discussed on the latest earnings call.
- 3Government purchasing and reimbursement rules, including China’s volume-based procurement, can affect medicine prices and sales.
关于Astrazeneca plc
AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.
- 总部
- Cambridge, England, United Kingdom
- 成立于
- 1992
- 上市于
- New York Stock Exchange
- 财年结束
- December 31
基于 Astrazeneca plc 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。